The Beijing IP Court has recently released a Report on patent linkage, which highlights the legal challenges that the courts may face in implementing the proposed linkage regime, entitled “Research on the China […]
China’s “Naked Bolar” and the Tapering Momentum to Protect Innovative Pharmaceuticals
There have been several important developments in recent weeks involving pharmaceutical IP protection in both mainland China and Taiwan. Based on these developments, mainland China appears to be slowing its momentum to […]
A Potpourri of AIPLA Legislative Comments — And Other Developments
The American Intellectual Property Law Association has once again made its comments on proposed changes to Chinese IP legislation (laws, regulations, rules, examination guidelines, judicial interpretations, etc. ) available to this blog. Attached […]
Draft of Data Exclusivity Rules Released by CFDA
CFDA just released on April 25, 2018, its Public Comment Draft of Pharmaceutical Data Exclusivity Implementing Rules (provisional) 药品试验数据保护实施办法（暂行）征求意见稿, available here (the web version is here). Comments are due by May 31, 2018, […]
April 3 – 9, 2018 Updates
1.China pushes generics over brands with another round of new pharma policies. The General Office of the State Council on April 3rd, 2018 issued “The Opinion on Reforming and Improving Supply and Use […]
IP House’s Snapshot of Medical and Health Industry
IP House has recently published a Statistical Report on IP Cases in the Medical and Health Industry (December 2017) (Chinese language) covering 391 medical and health industry cases closed from January 1, […]
More Policy Discussions on Pharma IP Reform
There appear to be some serious discussion of late regarding China using its IP laws to encourage more innovative drugs. One significant advance was the recent amendments to China’s Patent Examination Guidelines […]
